The estimated Net Worth of James Noble is at least $9.01 millió dollars as of 24 May 2019. Mr. Noble owns over 82,596 units of Adaptimmune Therapeutics Plc stock worth over $118,904 and over the last 9 years he sold ADAP stock worth over $6,066,000. In addition, he makes $2,821,740 as Non-Executive Director at Adaptimmune Therapeutics Plc.
James has made over 4 trades of the Adaptimmune Therapeutics Plc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 500,000 units of ADAP stock worth $4,665,000 on 29 May 2020.
The largest trade he's ever made was exercising 1,773,100 units of Adaptimmune Therapeutics Plc stock on 16 May 2019 worth over $248,234. On average, James trades about 165,981 units every 24 days since 2016. As of 24 May 2019 he still owns at least 110,096 units of Adaptimmune Therapeutics Plc stock.
You can see the complete history of Mr. Noble stock trades at the bottom of the page.
James Julian Noble serves as Non-Executive Director of the Company. He is our co-founder. From July 2008 until March 2014, Mr. Noble was also part-time CEO of Immunocore. Mr. Noble has 24 years of experience in the biotech industry. He has held numerous non-executive director positions, including at CuraGen Corporation, PowderJect Pharmaceuticals plc, Oxford GlycoSciences plc, Medigene AG, and Advanced Medical Solutions plc. Mr. Noble is also Deputy Chairman of GW Pharmaceuticals plc and a non-executive director of Immunocore Limited. Mr. Noble qualified as a chartered accountant with Pricewaterhouse Coopers and spent seven years at the investment bank Kleinwort Benson Limited, where he became a director in 1990. He then joined British Biotech plc as Chief Financial Officer from 1990 to 1997. Mr. Noble was previously Chief Executive Officer of Avidex Limited, a privately held biotechnology company that was our predecessor, from 2000 to 2006. Mr. Noble holds an M.A. from the University of Oxford. On June 10, 1999, the SEC completed an inquiry relating to two press announcements issued in 1995 and 1996 by British Biotech Plc, of which Mr. Noble was previously Chief Financial Officer. The SEC then filed an administrative complaint that those announcements and related periodic reports filed with the SEC were inaccurate and omitted to state material facts necessary to make the statements made therein not misleading. Under a final settlement reached with the SEC in June 1999, British Biotech Plc and three of its then directors including Mr. Noble agreed to the entry of an administrative order to continue to adhere to U.S. securities laws.
As the Non-Executive Director of Adaptimmune Therapeutics Plc, the total compensation of James Noble at Adaptimmune Therapeutics Plc is $2,821,740. There are no executives at Adaptimmune Therapeutics Plc getting paid more.
James Noble is 61, he's been the Non-Executive Director of Adaptimmune Therapeutics Plc since 2019. There are 3 older and 16 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.
James's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC,, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.
Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over $40,532,026 worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth $527,131,726 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of $2,827,332. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth $22,814.
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include: